Myotonic dystrophy (DM), or Steinert's disease, is an autosomal dominant disease characterized by myotonia, muscular weakness and atrophy, as well as lens opacities, cardiomyopathy and mild endocrine changes. The gene for DM located on 19q contains a triplet repeat at the 3Ј end of the gene. In DM patients, this repeat is found to be expanded. We have previously described a preimplantation genetic diagnosis (PGD) for DM using polymerase chain reaction (PCR) followed by conventional analysis on ethidium bromide-stained gels. The major drawback of this system was that allelic dropout occurred in Ͼ20% of the cells, leading to the loss of healthy embryos for transfer. To resolve this problem, we developed a PGD for DM using fluorescent PCR followed by fragment analysis on an automated DNA sequencer and made a comparison between the conventional PCR described earlier and fluorescent PCR, which turned out to be superior in accuracy and efficiency. Three PGD cycles were performed using fluorescent PCR and are described here.
Introduction
Myotonic dystrophy (DM), or Steinert's disease, is an autosomal dominant disease characterized by myotonia, weakness and atrophy affecting the face and sternomastoids as well as the distal, rather than proximal, muscles of the limbs, frontal baldness, lens opacity, gonadal atrophy in the male patients, cardiomyopathy and mild endocrine and bony changes (Harper, 1995) . The clinical picture can range from very mild disease with cataracts as the sole sign, to congenital DM, characterized by polyhydramnios and akinesia during pregnancy, and tented upper lip, respiratory inadequacy and pulmonary hypoplasia, talipes, poor motility and mental retardation in rare cases of survival. The molecular biology of the disease was elucidated in 1992 Mahadevan et al., 1992) when the gene located on 19q was cloned and shown to contain a CTG triplet repeat at the 3Ј end. This repeat is subject to expansion, and has 5-30 repeats in normal individuals, 50-80 repeats in mildly affected patients, and Ͼ200 repeats in severely affected patients. In the severest, neonatal form of the disease, the number of repeats can reach 2000 repeats and more. The increasing expansion of the repeat when transmitted to the next generation explains the phenomenon of anticipation, i.e. worsening of the disease over the generations. The repeat is highly polymorphic in the general population and we exploited this as a diagnostic tool by which to develop a preimplantation genetic diagnosis (PGD) for DM, based on the amplification of the non-expanded alleles using conventional polymease chain reaction (PCR) and separation of the PCR fragments on Metaphor ® agarose gels .
The major drawback of this assay was the high rate of allelic dropout (Ͼ20%), which led to the loss of several healthy embryos which were diagnosed as affected. Findlay et al. (1995a,b; 1996a,b,c) described the use of fluorescent PCR applied to single cells for purposes of PGD in their pioneering articles. One of the main advantages of fluorescent PCR, is that the allelic dropout (ADO) rate is much lower than in conventional PCR owing to the higher sensitivity of the method. We describe here the development and the application of fluorescent PCR to PGD for DM and make a comparison with the conventional PCR described earlier .
Materials and methods

Collection of single lymphoblasts
Epstein-Barr virus-transformed lymphoblasts were cultured according to standard procedures (Ventura et al., 1988) . A number of lymphoblast colonies were collected in 0.5 ml medium, transferred to a 1.5 ml Eppendorf tube and allowed to settle to the bottom of the tube. The supernatant was then removed, and the cells were washed three times with phosphate-buffered saline (PBS). This allows the collection of primarily living cells present in the colonies, rather than dead cells floating free in the medium. Single cells were then washed three times in 2 µl drops of Ca 2ϩ -and Mg 2ϩ -free medium in a Petri dish using fine hand-drawn microcapillaries which were blunted in a Narishige microforge. They were then transferred blindly to 2.5 or 5 µl alkaline lysis buffer (ALB, 200 mM KOH, 50 mM dithiothreitol) in 200 µl PCR tubes. For each three cells collected, one aliquot from the last washing droplet was transferred to a PCR tube to serve as a blank. The samples were kept at -80°C until further processing. . Informativity of the candidate couples was then checked by carrying out a fluorescent PCR on the couples' genomic DNA extracted from peripheral blood using primers DM101 and DM102 . A couple was considered to be informative if the healthy allele of the affected parent could be clearly distinguished from the alleles of the non-affected parent, since the diagnosis of a healthy embryo is based on the presence of the healthy allele of the affected parent . Table I shows the repeat lengths of the patients and their spouses.
Patient description
Patients nos. 1, 2, 3, 4, 5, 6 and 7 were described earlier by Sermon et al. (1997) and were denominated as nos. 6, 5, 1, 8, 7, 3, and 4 respectively. In this study, patients 8 and 9 are new patients and are described below.
Patient 8
Patient 8 is female, aged 32 years, nulligravid, nulliparous, has undergone no abortions, and has a 700 bp expansion of the gene. Age at diagnosis was 28 years. She is mildly affected, with an apparently negative family history. She has mitralis valve prolapse, but has no other complaints such as abnormal gait, nasal speech or ophtalmological symptoms. She is subfertile due to endometriosis (Stage III, American Fertility Society) and has tried unsuccessfully to conceive since 1990. The patient underwent four consecutive laparoscopies due to endometriosis, finally leading to left salpingectomy.
Patient 9
Patient 9 is male, aged 32 years. His wife is nulligravid, nulliparous, has undergone no abortions, and has a 250 bp expansion of the gene. The age of the patient at diagnosis was 28 years; he was completely asymptomatic, in whom the diagnosis was made through DNA investigations after DM was diagnosed both at the clinical and at the molecular level in his brother.
Collection of research blastomeres
Research blastomeres from embryos from our intracytoplasmic sperm injection (ICSI) programme which were unsuitable for transfer or for cryopreservation were collected as described earlier , after agreement was obtained from the donating patients and 792 the institutional ethical committee. A second group of embryos consisted of embryos diagnosed as affected after PGD using conventional PCR. Briefly, the zona pellucida was removed using acidic Tyrode's solution and the embryo was dissociated in Ca 2ϩ -and Mg 2ϩ -free medium containing 1 mg/ml trypsin. Single blastomeres were transferred to a 200 µl PCR tube in 2.5 µl alkaline lysis buffer. An aliquot from the last washing droplet served as a blank. The samples were kept at -80°C until further processing.
ICSI procedure
ICSI was used in all the cycles to prevent contamination with spermatozoa. The ICSI procedure was performed as described by Van Steirteghem et al. (1995) . Ovarian stimulation was carried out by a desensitizing protocol of the intranasally administered gonadotrophin-releasing hormone agonist buserelin (Suprefact ® ; Hoechst, Brussels, Belgium) in association with human menopausal gonadotrophins (HMG) (Humegon; Organon, Oss, The Netherlands; or Pergonal; Serono, Brussels, Belgium) and human chorionic gonadotrophin (HCG) (Pregnyl, Organon; or Profasi, Serono) (Smitz et al. 1988) . Oocyte retrieval was carried out by vaginal ultrasound-guided puncture of the ovarian follicles, 36 h after HCG administration. The cells of the cumulus and corona radiata were removed by a combination of an enzymatic and mechanical procedure. Only metaphase II oocytes were injected. The oocyte was immobilized by slight negative pressure exerted on the holding pipette. A single spermatozoon was injected into the ooplasm. The Petri dishes with the oocytes were incubated in 25 µl droplets of B2 medium in an incubator at 37°C (Heraeus, Vander Heyden, Brussels, Belgium; 5% O 2 , 5% CO 2 and 90% N 2 ). Fertilization was assessed 16-18 h after ICSI. Further development was evaluated in the morning of day 2 and again on day 3, when embryos were evaluated before biopsy.
Embryo biopsy
A hole was made in the zona pellucida by a stream of acidic Tyrode's using a fine needle. One or two blastomeres were then gently aspirated through the hole. In some embryos, compaction had already started, resulting in difficulties with the biopsy. These embryos were incubated for a few min in Ca 2ϩ -and Mg 2ϩ -free medium, after which a biopsy could be carried out without blastomeres sticking together . After biopsy, the blastomeres were checked for the presence of a nucleus and transferred to a 0.2 ml PCR tube containing 2.5 or 5 µl of alkaline lysis buffer. They were kept at -80°C for at least 30 min.
Cell lysis and PCR procedures
The cells were lysed by incubating them at 65°C for 10 min. The alkaline lysis buffer was then neutralized with 2.5 or 5 µl of a neutralization buffer (900 mM Tris-HCl pH 8.3, 300 mM KCl, 200 mM HCl). The reaction mixes for the first PCR (conventional PCR) and for the fluorescent PCR were decontaminated with the restriction enzyme HaeIII by incubation at 37°C for at least 3 h, followed by inactivation of the enzyme by incubation at 65°C for at least 20 min. The outer primers DM101 and DM102 were as described by Brook et al. (1992) . Reaction mix was added to the cells to a final volume of 50 µl and final concentrations of 10% dimethylsulphoxide (DMSO), 50 mM KCl, 100 mM Tris-HCl pH 8.3, 2 mM MgCl 2 , 0.1 mg/ml gelatin, 0.2 mM dNTP, 1 µM primers and 1.25 IU Taq polymerase (Perkin Elmer, Brussels, Belgium). PCR was carried out on a Perkin Elmer Cetus GeneAmp PCR System 9600 using the following programme: 5 min denaturation at 96°C, followed by 25 cycles of 30 s at 96°C, 30 s at 65°C and 30 s at 72°C, followed by 6 min at 72°C. The primers for the second PCR were DM409 and DM410 (Mahadevan et al., 1992) . Three µl from the first PCR were taken as a template in the second PCR. The reaction mix had the same final concentrations and volume as the first PCR, except that 1.5 mM MgCl 2 were used and no DMSO was added. The same PCR programme was used, except that the denaturation temperature was 94°C and 30 cycles were run. The PCR products were separated on a vertical 4% Metaphor ® Agarose gel (Sanver Tech, Boechout, Belgium), run at 350 V for 90 min. For the fluorescent PCR, the primer DM101 was labelled with a fluorescent tag (Eurogentec, Seraing, Belgium), while the primer DM 102 remained unlabelled. The total volume of the PCR reaction mix was 25 µl and had the same final concentrations as the first conventional PCR, except that only 0.2 µM of primers was used. The PCR programme was as follows: 5 min 96°C, 10 cycles of 96°C for 30 s, 65°C for 30 s, 72°C for 30 s, followed by 35 cycles of 94°C for 30 s, 65°C for 30 s, 72°C for 30 s, followed by 5 min 72°C. Three µl of the PCR product was mixed with 3 µl loading buffer (20 mM EDTA and 0.05% xylene cyanol in formamide) and loaded on the gel (6% acrylamide, 19:1 bis-acrylamide, 7 M urea, 1ϫ TBE, Sequencing Gel, Immunosource, Zoersel, Belgium). The electrophoresis unit used was an ALF Automated DNA Sequencer from Pharmacia Biotech. The results were processed using the Fragment Analyser software provided by the manufacturer. Figure 1a shows a PGD cycle carried out with conventional PGD, while Figure 1b shows results obtained with fluorescent PCR. Table I ). Lane 1; shows the healthy allele of the affected parent. Lane 6 shows the two alleles of the unaffected parent, as well as a heteroduplex. Lanes 2 and 3 show an affected embryo. Lane 4 shows a second affected embryo. Lane 5 shows a healthy embryo. This embryo was transferred. (b) An example of a PGD (cycle 1) using fluorescent PCR. The unaffected mother has 5 and 11 repeats, while the affected father has 13 repeats in his normal allele. Lane 1 shows a 50 bp ladder (100 and 150 bp are present). Lanes 2 and 3 are from an unaffected embryo with 5 (123 bp) and 13 (147 bp) repeats. Lanes 4 and 5 are from an affected embryo with 11 repeats (141 bp) and the expansion. Lane 6 is from an affected embryo with five repeats in its healthy allele. Lane 7 is empty (discarded using software). Lanes 8 and 9 are from an healthy embryo with 11 and 13 repeats. Lanes 18 and 19 show an unaffected embryo (five and 13 repeats), with allelic dropout in lane 18, where only the allele with five repeats is amplified. 
Figure 1. (a) Results obtained after preimplantation genetic diagnosis (PGD) using conventional polymerase chain reaction (PCR) (not shown in
Results
In a first step, we compared the efficiency and accuracy of our conventional and fluorescent PCR assays for DM on lymphoblasts, because here the genotype of the cells is known and a large series of cells can be examined. Using conventional PCR on cells heterozygous at the DM locus (five and 12 repeats), 38 out of 40 (95%) cells showed amplification. Of the 38 cells showing amplification, nine showed ADO (24%). These results agree well with our results obtained previously on research embryos (21% ADO, Sermon et al., 1997) . With fluorescent PCR, a much lower rate of ADO was found: 46 out of 49 heterozygous cells showed amplification (94%) and only three of these showed ADO (6.5%). The ADO rates in both groups are significantly different on the basis of the χ 2 test (P Ͻ 0.05). Results obtained afterwards with research blastomeres confirmed these first encouraging results: 65 blastomeres from 18 embryos were amplified using fluorescent PCR. Of these 69, 59 showed amplification (91%). In all, 19 blastomeres from five embryos were heterozygous; only one of these cells showed ADO (5.2%). Part of these results were discussed in Lissens and Sermon (1997) . Since we introduced the use of fluorescent PCR for clinical PGD for DM, we have carried out three PGDs for three different patients. To compare the results of these PGDs with the results from PGDs with conventional PCR, we pooled the results from the last 10 PGD cycles carried out with conventional PCR, because these cycles are comparable as regards other variables such as expertise in embryo biopsy. The eight first cycles are the same as the eight last cycles described in Sermon et al. (1997) . The details of these cycles are given in Table II (for conventional PCR) and  Table III (for fluorescent PCR) . Overall, in our 10 last PGD cycles using conventional PCR, 68 embryos were analysed from eight patients. A total of 105 cells were biopsied, 93 of which (89%) showed amplification. In all, 39 cells were shown to be heterozygous, either during the PGD itself, or when checking non-transferred embryos. Nine of these (23%) showed ADO; this figure is lower than the figure published previously for biopsied cells (32%, Sermon et al., 1997) , but agrees with the figure obtained from research blastomeres (21%). Two embryos diagnosed as affected during the PGD, were shown 794 afterwards not to be affected due to ADO and were thus lost for transfer. Using fluorescent PCR, three cycles were carried out on three different patients and 55 blastomeres were analysed from 34 embryos. The amplification rate was 50/55 (91%) and the ADO rate on heterozygous cells (as shown during PGD or after checking non-transferred embryos) was 1/22 (4.5%). Although this is a considerably different figure from the ADO obtained with conventional PCR (22 versus 4.5%), these figures were not found to be statistically different using the χ 2 test. The amplification rates and ADO rates of lymphoblasts and blastomeres are shown in Table IV . So far, no unaffected embryo was diagnosed as being affected as a result of PGD with fluorescent PCR. As shown in Table II , two of the patients whose embryos were analysed using conventional PCR became pregnant and both delivered healthy babies. None of the three patients whose embryos were analysed using fluorescent PCR became pregnant.
Discussion
We describe here a reliable and sensitive PCR for the PGD of myotonic dystrophy (DM), using fluorescent PCR and fragment analysis on an automated sequencer, developed primarily to reduce the high rate of ADO encountered with conventional PCR. ADO is defined as the failure of amplification of one or two alleles in a heterozygous cell. We have previously discussed the causes of and remedies to ADO . Briefly, ADO may be caused by one of the following phenomena: (i) the presence of haploid cells in an otherwise diploid embryo (or other forms of embryonal mosaicism); (ii) method of cell lysis used; (iii) the denaturation temperature at the beginning of the PCR cycle should be sufficiently high (e.g. 96°C) to completely denature the native DNA strand. A number of remedies have also been put forward: two cells should preferably be biopsied during a clinical PGD, and lysis conditions used (boiling in water gives higher ADO rates than lysis in alkaline lysis buffer) and PCR conditions should be optimized. To reduce our ADO rate even more, we opted for the development of fluorescent PCR. As described by Findlay et al. (1996a) , this method has a number of advantages over Sermon et al. (1997). conventional PCR: sensitivity is increased 1000-fold, accuracy is high (1-2 bp), multiplex PCR is very accurate, fewer PCR cycles are required, fluorescent PCR is highly accurate and reliable at the single cell level, and signals can easily be seen even if they are weak. This led these authors to propose a hypothesis of how fluorescent PCR lowers ADO: a number of cases of ADO are in fact preferential amplification, where one allele is so weakly amplified, that it cannot be detected by conventional analysis. Due to its greater sensitivity, fluorescent PCR clearly distinguishes between real cases of ADO and cases of extreme preferential amplification. We have previously described a PGD for DM based on a conventional PCR, which had as major drawback a high ADO rate (~20%). For conventional, as well as for fluorescent PCR, ADO will not lead to the transfer of affected embryos. In both these assays, affected embryos showed only one band (or peak), the healthy allele from the unaffected parent, while the expanded allele remained undetected. On the other hand, using this assay, healthy embryos are always heterozygous, carrying the healthy allele of the affected parent and one of the two healthy alleles of the unaffected parent. From this, it follows that ADO of the healthy allele of the affected parent will lead to a diagnosis of an affected embryo, as a result of which the embryo will not be transferred (i.e. acceptable error). If, on the contrary, the allele of the unaffected parent drops out, only the healthy allele of the affected parent will be seen and the conclusion of a healthy embryo and ADO will be drawn. Since ADO would not lead to the transfer of affected embryos with this assay, we were confident enough to carry out 22 cycles using the conventional assay. In this series, ADO led to the loss of seven embryos which were diagnosed as affected at PGD, but were shown to be unaffected after checking, out of a total of 795 51 embryos diagnosed as unaffected by PGD (14%). To alleviate this problem, we decided to develop a fluorescent PCR for DM. Findlay et al. (1995a,b) have described fluorescent single-cell PCR extensively and could show that the ADO rate was lowered considerably for different PCR assays, such as cystic fibrosis (∆F508) and amelogenin (used for sexing).
Our results presented here are in complete agreement with Findlay et al. (1995a,b) ; for lymphoblasts, there was a statistically significant reduction in ADO from 24 to 6.5%. A second encouraging fact was that the ADO found in research blastomeres was only 5.2% in comparison with 21% for conventional PCR. Finally, in clinical PGD, fluorescent PCR also turned out to be a far superior procedure to conventional PCR: only one out of 22 heterozygous cells showed ADO. However, the embryo from which this cell was biopsied was not wrongly diagnosed as affected because the second blastomere from this embryo showed the embryo to be unaffected. In conclusion, we may state that the use of a fluorescent PCR for PGD of DM is far superior to conventional PCR, because of its greater accuracy, leading to a much lower ADO rate and hence to a much smaller loss of embryos due to misdiagnosis. The use of fluorescent PCR should therefore certainly be recommended in assays where ADO might lead to the transfer of affected embryos, such as when the diagnosis of an autosomal dominant disease is based on the presence of the affected allele, or in recessive diseases where both parents carry different mutations and only one mutation is assessed.
